New publications
Preparations
Longitude
Longizada suppository is a medicine with proteolytic properties.
Indications of the longitude
Suppositories are indicated for the complex treatment of pathologies that develop with hyperplasia in the area of connective tissue. The medicine is prescribed in the following cases:
- urology - treatment of chronic form of prostatitis, interstitial form of cystitis, and in addition ureteric strictures with urethra, prostate adenoma (in the early stages of the disease), as well as Peyronie's disease;
- gynecology - the appearance of adhesions in the pelvic region, accompanied by inflammatory processes in the internal genital organs (among the diseases - endometritis in the chronic stage, Asherman's syndrome, and infertility of the tubal-peritoneal type);
- surgery - to eliminate the scarring of the hypertrophic type (among those obtained as a result of injuries, burns, surgeries, and pyoderma), adhesions developing as a result of abdominal surgery, and in addition to long-healing wounds;
- dermatovenereology and cosmetology - elimination of developing hypertrophic or keloid scars developing after surgery, trauma, as well as burns or pyoderma, and also for the treatment of a limited form of scleroderma;
- phthisiology and pulmonology - pulmonary pneumosclerosis, infiltrative or cavernous-fibrous form of tuberculosis, pulmonary tuberculoma, fibrotic type alveolitis, and in addition siderosis with pneumofibrosis, as well as interstitial form of pneumonia and pleurisy;
- orthopedics - treatment of limited joint mobility, hematomas, Bechterew's disease, as well as arthrosis.
In addition, the suppository can be used to increase the bioavailability of antimicrobial drugs, as well as local anesthetics in pulmonology, urology, and dermatovenereology and gynecology.
For medical purposes, Longidase can be used to prevent the occurrence of scars or strictures after surgical operations.
Pharmacodynamics
Longidase is a complex of macromolecules entering the proteolytic enzyme of hyaluronidase and having a high molecular weight carrier. The carrier is an element from the category of N-hydroxy-poly-1,4-ethylene piperazine derivatives. Longidazu is distinguished by the powerful activity of hyaluronidase (it is several times higher than the activity of native-type hyaluronidase), which develops because the conjugate is more resistant to the effects of slowing components, as well as temperatures.
The drug has powerful anti-inflammatory, immunostimulating, anti-edema, antioxidant, and also chelating properties. Hyaluronidase contains specific substrates, which are glycosaminoglycans - the elements of connective tissues, among which chondroitin-4-sulfate, as well as chondroitin-6-sulfate, and in addition hyaluronan with chondroitin. The glycolysis process makes it possible to reduce the viscosity of glycosaminoglycans and, at the same time, the ability to synthesize metal ions with water. As a result, tissue trophism and permeability increase, resorption with hematomas and a reduction in the swelling, and in addition, the elasticity of the areas on which the scars are located improves. The glycolysis of these elements also allows to reduce the severity or completely remove the limited joint mobility and adhesions.
The most effective medicine will be in case of its use at the initial stages of treatment of the disease.
The antioxidant property of Longidase is ensured by the ability of the active ingredient to synthesize iron ions. These substances activate the response of free radicals, and in addition stimulate the processes of collagen binding and slowing down of hyaluronidase.
The pronounced antifibrotic effect of the drug is proved by a multitude of biochemical, electron microscopic, and histological tests performed on a sample of pneumofibrosis.
Suppositories normalize the process of synthesis of inflammation conductors, promote the strengthening of humoral immunity, and at the same time reduce the intensity of manifestations of inflammation during the acute stage of the disease.
The drug can be used to prevent the development of adhesions or scars after surgery, because it does not have a negative effect on the course of the postoperative period and does not provoke the progression of the infection. In addition, it does not interfere with the restorative process inside bone tissues.
Through the use of drugs, the level of bioavailability of other drugs increases, and with it the development of the effect of the use of local anesthetics is accelerated.
Longidase has a weak toxicity, the active substance of the drug does not affect the functioning of the immune and reproductive systems. It has no mutagenic, carcinogenic, and teratogenic properties.
Pharmacokinetics
After rectal administration, the active substance of the drug is rapidly absorbed into the systemic blood stream, after which it reaches its maximum values within 1 hour. After rectal or vaginal administration, the bioavailability of the substance is 70%.
The active component is able to pass through the BBB, the placenta, and also the ophthalmologic barrier. The carrier that is inside the body disintegrates, taking the form of oligomers, excreted through the kidneys in 2 phases.
The half-life of the substance after vaginal or rectal administration is 42-84 hours.
Contraindications
Among the contraindications of drugs:
- It is forbidden in case of patient intolerance of the constituent elements of the medicine;
- Do not use in the treatment of people with severe renal function disorders or malignant tumors;
- is not assigned to children less than 12 years of age.
Caution is prescribed for people with kidney failure, and also for those who have recently had bleeding. In addition, caution is required if the patient has an infectious process in acute form (in such a situation, the suppository can be administered exclusively in combination with antimicrobial drugs).
Dosing and administration
Suppositories with a drug should be administered vaginally (from lying down before bedtime) or rectally (only after bowel movement). The size of the dose, as well as the duration of the course of therapy, are prescribed by the treating doctor.
For the treatment of urological pathologies, one suppository should be administered rectally every 1 to 48 hours. After 10 introduced suppositories, the interval between applications should be increased to 2-3 days. In general, 20 candles are required for the course.
With the elimination of gynecological diseases, 1 suppository is administered vaginally or rectally once per 3 days. The general course of therapy includes 10 suppositories. If there is a need, after the main course, the appointment of maintenance treatment is possible.
For treatment of dermatovenereological diseases, it is necessary to administer 1 suppository rectally every 2-3 days. In general, the entire course includes 10-15 candles.
To eliminate surgical disorders, rectal administration of the first suppository is given once with an interval of 2-4 days. In general, the course usually consists of 10 candles.
In the process of treatment of phthisiatric and pulmonological diseases, rectal administration of the first suppository is prescribed once with intervals of 3-5 days. The general course includes the introduction of 10-20 suppositories of the drug.
Prescribe a repeat therapeutic course usually can be at least 3 months after the end of the previous one. Supportive treatment includes the introduction of the first suppository once with intervals of 5-7 days for 3-4 months.
For people who have recently experienced bleeding, as well as those suffering from a chronic form of kidney failure, the recommended dosage is no more than 1 suppository once per 7 days.
Interactions with other drugs
The drug enhances the properties of diuretics and antimicrobial drugs, as well as local anesthetic drugs when combined with them.
In the case of simultaneous use with estrogens, salicylates, corticotropin, and antihistamine drugs (all in high doses), the properties of Longidase are weakened.
It is forbidden to combine the drug with phenytoin, furosemide, as well as benzodiazepines.